PrecISE: Precision Medicine in Severe Asthma: An adaptive platform trial with biomarker ascertainment.

MLA

Israel, Elliot, et al. “PrecISE: Precision Medicine in Severe Asthma: An Adaptive Platform Trial with Biomarker Ascertainment.” The Journal of Allergy and Clinical Immunology, vol. 147, no. 5, May 2021, pp. 1594–601. EBSCOhost, https://doi.org/10.1016/j.jaci.2021.01.037.

APA

Israel, E., Denlinger, L. C., Bacharier, L. B., LaVange, L. M., Moore, W. C., Peters, M. C., Georas, S. N., Wright, R. J., Mauger, D. T., Noel, P., Akuthota, P., Bach, J., Bleecker, E. R., Cardet, J. C., Carr, T. F., Castro, M., Cinelli, A., Comhair, S. A. A., Covar, R. A., … Ivanova, A. (2021). PrecISE: Precision Medicine in Severe Asthma: An adaptive platform trial with biomarker ascertainment. The Journal of Allergy and Clinical Immunology, 147(5), 1594–1601. https://doi.org/10.1016/j.jaci.2021.01.037

Chicago

Israel, Elliot, Loren C Denlinger, Leonard B Bacharier, Lisa M LaVange, Wendy C Moore, Michael C Peters, Steve N Georas, et al. 2021. “PrecISE: Precision Medicine in Severe Asthma: An Adaptive Platform Trial with Biomarker Ascertainment.” The Journal of Allergy and Clinical Immunology 147 (5): 1594–1601. doi:10.1016/j.jaci.2021.01.037.